Search results for "Lorcaserin"

showing 3 items of 3 documents

Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats

2020

Abstract Lorcaserin, which is a selective agonist of serotonin2C receptors (5-HT2CRs), is a new FDA-approved anti-obesity drug that has also shown therapeutic promise in other brain disorders, such as addiction and epilepsy. The modulation of dopaminergic function might be critical in the therapeutic effect of lorcaserin, but its exact effect is unknown. Here, we studied the effect of the peripheral administration of lorcaserin on the ventral tegmental area (VTA), the substantia nigra pars compacta (SNc) dopaminergic neural activity, dopamine (DA) dialysis levels in the nucleus accumbens and striatum and on DA tissue levels in 29 different rat brain regions. Lorcaserin (5–640 μg/kg, i.v.) m…

0301 basic medicineMalemedicine.medical_specialtySerotoninDopamineSubstantia nigraStriatumNucleus accumbensSettore BIO/09 - FisiologiaLorcaserinIntracerebral microdialysisRats Sprague-DawleyDose-Response Relationship03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineSingle cell extracellular recordingsRewardDopamineInternal medicineReceptor Serotonin 5-HT2CmedicineAnimals5-HT2CObesityPharmacologyDose-Response Relationship DrugPars compactaChemistryDopaminergic NeuronsDopaminergicBrainNeurochemistryBenzazepinesSerotonin2C receptorRatsVentral tegmental area030104 developmental biologyEndocrinologymedicine.anatomical_structurenervous systemSprague-DawleyDrugIntracerebral microdialysis; Neurochemistry; Obesity; Reward; Serotonin2C receptor; Single cell extracellular recordings; Animals; Benzazepines; Brain; Dopamine; Dopaminergic Neurons; Dose-Response Relationship Drug; Male; Rats; Rats Sprague-Dawley; Receptor Serotonin 5-HT2C; Serotonin 5-HT2 Receptor AgonistsIntracerebral microdialysi030217 neurology & neurosurgerySerotonin 5-HT2 Receptor Agonistsmedicine.drugReceptor
researchProduct

Role(s) of the 5-HT2C receptor in the development of maximal dentate activation in the hippocampus of anesthetized rats.

2014

Aims: Substantial evidence indicates that 5-HT2C receptors are involved in the control of neuronal network excitability and in seizure pathophysiology. Here, we have addressed the relatively unexplored relationship between temporal lobe epilepsy (TLE), the most frequent type of intractable epilepsy, and 5-HT2CRs. Methods: In this study, we investigated this issue using a model of partial complex (limbic) seizures in urethane-anesthetized rat, based on the phenomenon of maximal dentate activation (MDA) using 5-HT2C compounds, electrophysiology, immunohistochemistry, and western blotting techniques. Results: The 5-HT2C agonists mCPP (1 mg/kg, i.p) and lorcaserin (3 mg/kg, i.p), but not RO60-0…

MaleSerotonin receptorsmedicine.medical_specialtyGlutamate decarboxylaseDentate gyrus; Depression; GABA; Memory; Serotonergic2c drugs; Serotonin receptors; Temporal lobe epilepsyHippocampusHippocampal formationDentate gyruEpileptogenesisSettore BIO/09 - FisiologiaHippocampusDentate gyrus; Depression; GABA; Memory;LorcaserinRats Sprague-DawleySerotonergic 2c drugGABAEpilepsyMemoryDentate gyrus; Depression; GABA; Memory; Serotonin receptors; Temporal lobe epilepsyPhysiology (medical)Internal medicinemedicineReceptor Serotonin 5-HT2CAnimalsDentate gyrusPharmacology (medical)Serotonin receptorTemporal lobe epilepsyPharmacologyDepressionChemistryDentate gyrusDentate gyrus;Depression; GABA; Memory; Serotonergic2c drugs; Serotonin receptors; Temporal lobe epilepsyOriginal Articlesmedicine.diseaseRats5-HT2C receptorPsychiatry and Mental healthEndocrinologyDepression MentalEpilepsy Temporal LobeDentate GyrusSerotonergic2c drugAnesthetics IntravenousSerotonin 5-HT2 Receptor Agonistsmedicine.drug
researchProduct

Novel anti-obesity drugs and plasma lipids

2014

Obesity is a health problem of global, epidemic proportions and a major risk factor for chronic diseases resulting in accelerated morbidity and mortality. Dyslipidemia with a predominance of small dense LDL, impaired functionality of HDL particles, and increased serum levels of remnant particles due to impaired clearance of triglyceriderich lipoproteins significantly heightens cardiovascular events in obese subjects. Pharmacotherapy in combination with lifestyle modification is the primary approach to reduce obesity-related cardiovascular risk. Although there are several potential anti-obesity drugs, orlistat is the only agent that remains available in the market. Lorcaserin and Qsymia ® , …

business.industryEndocrinology Diabetes and MetabolismTherapeutic effectPharmacologymedicine.diseaseObesityanti-obesity drugs contrave dyslipidemia lorcaserin low-density lipoprotein obesity Qsymia® triglycerideLorcaserinOrlistatPharmacotherapymedicineRisk factorCardiology and Cardiovascular MedicineAdverse effectbusinessDyslipidemiamedicine.drug
researchProduct